Open access
Jul 2026
CAR19 Tregs treat murine chronic graft-versus-host disease through immune suppression without measurable B cell cytolysis
The findings suggest that CAR19 Tregs represent a promising and safe cGVHD/BOS therapeutic strategy, offering immunosuppressive benefits and improved disease outcomes that may be more limited with CD8+ CAR19 T cell treatment.
Sujeong Jin, Michael C. Zaiken, Cameron McDonald-Hyman et al.
· JCI Insight · 0 citations